COLL
Price
$37.74
Change
+$0.58 (+1.56%)
Updated
Aug 15 closing price
Capitalization
1.17B
82 days until earnings call
VTRS
Price
$10.61
Change
-$0.08 (-0.75%)
Updated
Aug 15 closing price
Capitalization
12.46B
86 days until earnings call
Interact to see
Advertisement

COLL vs VTRS

Header iconCOLL vs VTRS Comparison
Open Charts COLL vs VTRSBanner chart's image
Collegium Pharmaceutical
Price$37.74
Change+$0.58 (+1.56%)
Volume$352.19K
Capitalization1.17B
Viatris
Price$10.61
Change-$0.08 (-0.75%)
Volume$9.23M
Capitalization12.46B
COLL vs VTRS Comparison Chart in %
Loading...
COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
COLL vs. VTRS commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COLL is a Hold and VTRS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (COLL: $37.16 vs. VTRS: $10.69)
Brand notoriety: COLL and VTRS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: COLL: 119% vs. VTRS: 122%
Market capitalization -- COLL: $1.17B vs. VTRS: $12.46B
COLL [@Pharmaceuticals: Generic] is valued at $1.17B. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $12.46B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.83B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.72B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COLL’s FA Score shows that 1 FA rating(s) are green whileVTRS’s FA Score has 2 green FA rating(s).

  • COLL’s FA Score: 1 green, 4 red.
  • VTRS’s FA Score: 2 green, 3 red.
According to our system of comparison, COLL is a better buy in the long-term than VTRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COLL’s TA Score shows that 6 TA indicator(s) are bullish while VTRS’s TA Score has 5 bullish TA indicator(s).

  • COLL’s TA Score: 6 bullish, 4 bearish.
  • VTRS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, COLL is a better buy in the short-term than VTRS.

Price Growth

COLL (@Pharmaceuticals: Generic) experienced а +12.81% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was +13.84% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.

Reported Earning Dates

COLL is expected to report earnings on Nov 06, 2025.

VTRS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($12.5B) has a higher market cap than COLL($1.17B). VTRS has higher P/E ratio than COLL: VTRS (236.20) vs COLL (35.06). COLL YTD gains are higher at: 29.703 vs. VTRS (-11.810). COLL has higher annual earnings (EBITDA): 333M vs. VTRS (-530.8M). VTRS has more cash in the bank: 1B vs. COLL (198M). COLL has less debt than VTRS: COLL (844M) vs VTRS (14.5B). VTRS has higher revenues than COLL: VTRS (14.3B) vs COLL (664M).
COLLVTRSCOLL / VTRS
Capitalization1.17B12.5B9%
EBITDA333M-530.8M-63%
Gain YTD29.703-11.810-252%
P/E Ratio35.06236.2015%
Revenue664M14.3B5%
Total Cash198M1B20%
Total Debt844M14.5B6%
FUNDAMENTALS RATINGS
COLL vs VTRS: Fundamental Ratings
COLL
VTRS
OUTLOOK RATING
1..100
1425
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
12
Undervalued
PROFIT vs RISK RATING
1..100
39100
SMR RATING
1..100
4796
PRICE GROWTH RATING
1..100
4247
P/E GROWTH RATING
1..100
61
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (12) in the null industry is somewhat better than the same rating for COLL (69) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew somewhat faster than COLL’s over the last 12 months.

COLL's Profit vs Risk Rating (39) in the Pharmaceuticals Other industry is somewhat better than the same rating for VTRS (100) in the null industry. This means that COLL’s stock grew somewhat faster than VTRS’s over the last 12 months.

COLL's SMR Rating (47) in the Pharmaceuticals Other industry is somewhat better than the same rating for VTRS (96) in the null industry. This means that COLL’s stock grew somewhat faster than VTRS’s over the last 12 months.

COLL's Price Growth Rating (42) in the Pharmaceuticals Other industry is in the same range as VTRS (47) in the null industry. This means that COLL’s stock grew similarly to VTRS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is in the same range as COLL (6) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew similarly to COLL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COLLVTRS
RSI
ODDS (%)
Bearish Trend 3 days ago
69%
Bearish Trend 3 days ago
67%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
70%
Bearish Trend 3 days ago
56%
Momentum
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
59%
MACD
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
62%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 3 days ago
64%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 3 days ago
62%
Advances
ODDS (%)
Bullish Trend 6 days ago
72%
Bullish Trend 3 days ago
67%
Declines
ODDS (%)
Bearish Trend 3 days ago
63%
Bearish Trend 17 days ago
66%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
65%
Bearish Trend 3 days ago
64%
Aroon
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
53%
View a ticker or compare two or three
Interact to see
Advertisement
COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WBAIX17.11-0.03
-0.18%
Weitz Conservative Allocation-Instl Cl
JVAQX39.78-0.07
-0.18%
JPMorgan Value Advantage R4
NWAPX36.44-0.07
-0.19%
Nationwide BNY Mellon Dyn US Eq Inc Egl
LAVQX15.86-0.06
-0.38%
Lord Abbett Fundamental Equity R2
GCEEX9.66-0.09
-0.92%
Goldman Sachs Clean Energy Income R6

COLL and

Correlation & Price change

A.I.dvisor indicates that over the last year, COLL has been loosely correlated with AMPH. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if COLL jumps, then AMPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COLL
1D Price
Change %
COLL100%
-1.85%
AMPH - COLL
43%
Loosely correlated
-0.89%
AMRX - COLL
38%
Loosely correlated
-0.11%
ALKS - COLL
37%
Loosely correlated
-1.29%
VTRS - COLL
36%
Loosely correlated
+2.69%
PAHC - COLL
36%
Loosely correlated
-1.26%
More

VTRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VTRS has been loosely correlated with ELAN. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if VTRS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
+2.69%
ELAN - VTRS
54%
Loosely correlated
+1.07%
ZTS - VTRS
47%
Loosely correlated
+0.41%
AMRX - VTRS
47%
Loosely correlated
-0.11%
EBS - VTRS
44%
Loosely correlated
+0.34%
PAHC - VTRS
40%
Loosely correlated
-1.26%
More